erlotinib hydrochloride has been researched along with glucagon-like peptide 2 in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (glucagon-like peptide 2) | Trials (glucagon-like peptide 2) | Recent Studies (post-2010) (glucagon-like peptide 2) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 798 | 64 | 442 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hare, KJ; Hartmann, B; Holst, JJ; Poulsen, SS; Rasmussen, AR; Thim, L; Viby, NE | 1 |
1 other study(ies) available for erlotinib hydrochloride and glucagon-like peptide 2
| Article | Year |
|---|---|
The intestinotrophic peptide, GLP-2, counteracts the gastrointestinal atrophy in mice induced by the epidermal growth factor receptor inhibitor, erlotinib, and cisplatin.
Topics: Animals; Antineoplastic Agents; Atrophy; Body Weight; Cisplatin; Dose-Response Relationship, Drug; Drug Interactions; Erlotinib Hydrochloride; Female; Gastroenteritis; Gastrointestinal Tract; Glucagon-Like Peptide 2; Mice; Mice, Inbred Strains; Protein Kinase Inhibitors; Quinazolines | 2010 |